Avadel announces publications in cns drugs supplement highlighting key clinical issues for people with narcolepsy and their clinicians

Dublin, march 25, 2025 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a cns drugs supplement titled “a new dawn in the management of narcolepsy”.
AVDL Ratings Summary
AVDL Quant Ranking